The FDA has approved the first multitarget stool RNA test for colorectal cancer screening in typical average-risk adults 45 years of age and older.
The approval of the test, ColoSense (Geneoscopy), comes following positive results of its CRC-PREVENT trial (JAMA 2023;330[18]:1760-1768). In the trial, researchers found the mt-sRNA test achieved a sensitivity of 94% for CRC and 46% for advanced adenomas. In addition, the researchers found a sensitivity of 100% for CRC and 44% for advanced adenomas